Biologics and global burden of asthma: A worldwide portrait and a call for action

Biologics for severe asthma can significantly impact on the burden of disease and also have the potential to reduce asthma mortality. By reviewing the literature and contacting the pharmaceutical companies, the present paper aims at providing a worldwide snapshot of biologic drugs availability, rela...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The World Allergy Organization journal Ročník 14; číslo 2; s. 100502
Hlavní autoři:	Caminati, M., Morais-Almeida, M., Bleecker, E., Ansotegui, I., Canonica, G.W., Bovo, C., Senna, G.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 01.02.2021 Elsevier BV World Allergy Organization Elsevier
Témata:	Allergies Asthma Asthma costs Asthma mortality Biological products Biologics Chronic obstructive pulmonary disease Drugs Health care access Health care expenditures High income Low income groups Monoclonal antibodies Morbidity Mortality Pharmaceutical industry Risk factors Severe asthma Severe asthma prevalence Socioeconomic factors Steroids South Korea United States > US Asia Japan Europe Africa Israel North America Russia Asthma costs Severe asthma Severe asthma prevalence Asthma mortality Biologics
ISSN:	1939-4551, 1939-4551
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!